﻿
                         SEQUENCE LISTING

<110>  STAIDSON (BEIJING) BIOPHARMACEUTICALS CO. , LTD.；BEIJING NUOWEIKANG MEDICINE TECHNOLOGY CO., LTD. 

<120>  ACTIVATORS OF COAGULATION FACTOR X AND FORMULATIONS THEREOF FOR TREATING BLEEDING DISORDERS

<160>  5

<210>  1 (RVV-X heavy chain or α chain)
<211>  431
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  Synthetic Construct

<400>  1 (RVV-X heavy chain or α chain)
Leu Val Ala Thr Ser Ala Gln Phe Asn Lys Ala Phe Ile Glu Leu Ile
  1               5                  10                  15     
Ile Ile Val Asp His Ser Met Ala Lys Lys Cys Asn Ser Thr Ala Thr
             20                  25                  30         
Asn Thr Lys Ile Tyr Glu Ile Val Asn Ser Ala Asn Glu Ile Phe Asn
         35                  40                  45             
Pro Leu Asn Ile His Val Thr Leu Ile Gly Val Glu Phe Trp Cys Asp
     50                  55                  60                 
Arg Asp Leu Ile Asn Val Thr Ser Ser Ala Asp Glu Thr Leu Asp Ser
 65                  70                  75                  80 
Phe Gly Glu Trp Arg Ala Ser Asp Leu Met Thr Arg Lys Ser His Asp
                 85                  90                  95     
Asn Ala Leu Leu Phe Thr Asp Met Arg Phe Asp Leu Asn Thr Leu Gly
            100                 105                 110         
Ile Thr Phe Leu Ala Gly Met Cys Gln Ala Tyr Arg Ser Val Gly Ile
        115                 120                 125             
Val Gln Val Gln Gly Asn Arg Asn Phe Lys Thr Ala Val Ile Met Ala
    130                 135                 140                 
His Glu Leu Ser His Asn Leu Gly Met Tyr His Asp Gly Lys Asn Cys
145                 150                 155                 160 
Ile Cys Asn Asp Ser Ser Cys Val Met Ser Pro Val Leu Ser Asp Gln
                165                 170                 175     
Pro Ser Lys Leu Phe Ser Asn Cys Ser Ile His Asp Tyr Gln Arg Tyr
            180                 185                 190         
Leu Thr Arg Tyr Lys Pro Lys Cys Ile Leu Tyr Pro Pro Leu Arg Lys
        195                 200                 205             
Asp Ile Val Ser Pro Pro Val Cys Gly Asn Glu Ile Trp Glu Glu Gly
    210                 215                 220                 
Glu Glu Cys Asp Cys Gly Ser Pro Ala Asp Cys Gln Asn Pro Cys Cys
225                 230                 235                 240 
Asp Ala Ala Thr Cys Lys Leu Lys Pro Gly Ala Glu Cys Gly Asn Gly
                245                 250                 255     
Leu Cys Cys Tyr Gln Cys Lys Ile Lys Thr Ala Gly Thr Val Cys Arg
            260                 265                 270         
Arg Ala Arg Asn Glu Cys Asp Val Pro Glu His Cys Thr Gly Gln Ser
        275                 280                 285             
Ala Glu Cys Pro Arg Asp Gln Leu Gln Gln Asn Gly Gln Pro Cys Gln
    290                 295                 300                 
Asn Asn Arg Gly Tyr Cys Tyr Asn Gly Asp Cys Pro Ile Met Arg Asn
305                 310                 315                 320 
Gln Cys Ile Ser Leu Phe Gly Ser Arg Ala Asn Val Ala Lys Asp Ser
                325                 330                 335     
Cys Phe Gln Glu Asn Leu Lys Gly Ser Tyr Tyr Gly Tyr Cys Arg Lys
            340                 345                 350         
Glu Asn Gly Arg Lys Ile Pro Cys Ala Pro Gln Asp Val Lys Cys Gly
        355                 360                 365             
Arg Leu Phe Cys Leu Asn Asn Ser Pro Gly Asn Lys Asn Pro Cys Asn
    370                 375                 380                 
Met His Tyr Ser Cys Met Asp Gln His Lys Gly Met Val Asp Pro Gly
385                 390                 395                 400 
Thr Lys Cys Glu Asp Gly Lys Val Cys Asn Asn Lys Arg Gln Cys Val
                405                 410                 415     
Asp Val Asn Thr Ala Tyr Gln Ser Thr Thr Gly Phe Ser Gln Ile
            420                 425                 430     


<210>  2 (RVV-X light chain 1 or γ chain)
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  Synthetic Construct

<400>  2 (RVV-X light chain 1 or γ chain)
Val Leu Asp Cys Pro Ser Gly Trp Leu Ser Tyr Glu Gln His Cys Tyr
  1               5                  10                  15     
Lys Gly Phe Asn Asp Leu Lys Asn Trp Thr Asp Ala Glu Lys Phe Cys
             20                  25                  30         
Thr Glu Gln Lys Lys Gly Ser His Leu Val Ser Leu His Ser Arg Glu
         35                  40                  45             
Glu Glu Glu Phe Val Val Asn Leu Ile Ser Glu Asn Leu Glu Tyr Pro
     50                  55                  60                 
Ala Thr Trp Ile Gly Leu Gly Asn Met Trp Lys Asp Cys Arg Met Glu
 65                  70                  75                  80 
Trp Ser Asp Arg Gly Asn Val Lys Tyr Lys Ala Leu Ala Glu Glu Ser
                 85                  90                  95     
Tyr Cys Leu Ile Met Ile Thr His Glu Lys Glu Trp Lys Ser Met Thr
            100                 105                 110         
Cys Asn Phe Ile Ala Pro Val Val Cys Lys Phe
        115                 120             


<210>  3 (RVV-X light chain 2 or β chain)
<211>  135
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  Synthetic Construct

<400>  3 (RVV-X light chain 2 or β chain)
Gly Leu Asp Cys Pro Pro Asp Ser Ser Leu Tyr Arg Tyr Phe Cys Tyr
  1               5                  10                  15     
Arg Val Phe Lys Glu His Lys Thr Trp Glu Ala Ala Glu Arg Phe Cys
             20                  25                  30         
Met Glu His Pro Asn Asn Gly His Leu Val Ser Val Glu Ser Met Glu
         35                  40                  45             
Glu Ala Glu Phe Val Ala Lys Leu Leu Ser Asn Ile Thr Glu Lys Phe
     50                  55                  60                 
Ile Thr His Phe Trp Ile Gly Leu Met Ile Lys Asp Lys Glu Gln Glu
 65                  70                  75                  80 
Cys Ser Ser Glu Trp Ser Asp Gly Ser Ser Val Ser Tyr Asp Asn Leu
                 85                  90                  95     
Asp Lys Arg Glu Phe Arg Lys Cys Phe Val Leu Glu Lys Glu Ser Gly
            100                 105                 110         
Tyr Arg Met Trp Phe Asn Arg Asn Cys Glu Glu Arg Tyr Leu Phe Val
        115                 120                 125             
Cys Lys Val Pro Pro Glu Cys
    130                 135 


<210>  4
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  Synthetic Construct

<400>  4
(Suc)Ile Gly(γPip) Gly Arg(pNA)
        1             


<210>  5 (RVV-X light chain 1 or γ chain)
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>  
<223>  Synthetic Construct

<400>  5 (RVV-X light chain 1 or γ chain)
Val Leu Asp Cys Pro Ser Gly Trp Leu Ser Tyr Glu Gln His Cys Tyr
  1               5                  10                  15     
Lys Gly Phe Asn Asp Leu Lys Asn Trp Thr Asp Ala Glu Lys Phe Cys
             20                  25                  30         
Thr Glu Gln Lys Lys Gly Ser His Leu Val Ser Leu His Ser Arg Glu
         35                  40                  45             
Glu Glu Lys Phe Val Val Asn Leu Ile Ser Glu Asn Leu Glu Tyr Pro
     50                  55                  60                 
Ala Thr Trp Ile Gly Leu Gly Asn Met Trp Lys Asp Cys Arg Met Glu
 65                  70                  75                  80 
Trp Ser Asp Arg Gly Asn Val Lys Tyr Lys Ala Leu Ala Glu Glu Ser
                 85                  90                  95     
Tyr Cys Leu Ile Met Ile Thr His Glu Lys Val Trp Lys Ser Met Thr
            100                 105                 110         
Cys Asn Phe Ile Ala Pro Val Val Cys Lys Phe
        115                 120             


                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    